14 November 2022 | News
Expected to reach industrial-scale production levels with an output value of $1.38 billion in three to five years
image credit- prnewswire
Genesis MedTech Group, based in Singapore, has officially unveiled its state-of-the-art medtech campus in Wuxi, China. Representing the first major R&D and manufacturing facility of its kind in China, it spans 135,333 sqm and has completed its first phase of development, featuring an innovation centre, and two R&D and production centres.
The Innovation Centre provides an open educational platform to foster deeper engagement and interaction between Genesis MedTech and medical professionals. It provides medical professionals access to clinical training of the latest medtech innovations, covering multiple disease fields, such as minimally invasive surgery, vascular interventions and structural heart disease.
The training facilities within the Innovation Centre provide the highest level of education and hands-on experience, recreating real-life clinical situations for healthcare practitioners to understand and familiarise themselves with cutting-edge medical devices.
The Campus also houses the R&D and Manufacturing Centre, which develops and manufactures high-quality medical devices, focusing on cutting-edge medtech devices for minimally invasive surgery and vascular interventions. Pilot manufacturing commenced in September 2022 and is scheduled for full-scale production by 1H2023. It is expected to reach industrial-scale production levels with an output value of over 10 billion RMB (approximately $1.38 billion) in three to five years.